Eli Lilly Shares Surge on Raised Sales Forecast
· bloomberg.com · popularity 36/100 · 0 similar stories today
Read the original at bloomberg.com →
Summary
Eli Lilly & Co. raised its full-year sales forecast as demand for its blockbuster obesity and diabetes drugs continues to surge. Speaking on "Bloomberg Open Interest," Bloomberg's Madison Muller also discusses the implications for Novo Nordisk. (Source: Bloomberg)
Found in: Bloomberg Markets. Rating basis: single outlet; outlet tier 5; 1 feeds; feed position 16.